Press Releases

A new study by researchers at Memorial Sloan Kettering Cancer Center finds that even the sickest cancer patients are willing and able to "self-report" symptoms using the Internet, thus supplying key data in real time to their healthcare providers.

According to a new study published online today in the <I>Journal of the National Cancer Institute</I>, prostate cancer patients treated by highly experienced surgeons are much more likely to be cancer-free five years after surgery than patients treated by surgeons with less experience.

Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

May 23, 2007 NEW YORK - The Bright Horizons Foundation for Children, Memorial Sloan Kettering Cancer Center (MSKCC), Abyssinian Development Corporation (ADC), and Community Playthings today cut ribbons to officially open Harlem's first Bright Space center for homeless children at Abyssinian House, a Tier II transitional residence serving the families of Harlem.

Patients with primary gastrointestinal stromal tumor, a type of tumor found in the stomach or small intestine, who received imatinib (Gleevec ®) after complete removal of their tumor were significantly less likely to have a recurrence of the cancer compared to those who did not receive imatinib.

A newly published study demonstrates that imaging with Positron Emission Tomography (PET) using a radiolabeled antibody accurately identifies whether a patient has clear cell renal carcinoma - the most common and aggressive type of renal tumor - and arms the urologist with crucial information that will help determine whether surgery is needed.